Related Experiment Video

Updated: Jul 7, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

[Prevalence of undetected chronic kidney disease in dyslipidemic population treated in primary care. LIPICAP study]

José L Llisterri Caro1, José L Gorriz Teruel, Francisco J Alonso Moreno

  • 1Centro de Salud Joaquín Benlloch, Valencia, España. jllisterric@medynet.com

Medicina Clinica
|February 19, 2008
PubMed

Insights

Undetected chronic kidney disease (CKD) affects nearly 20% of dyslipidemic patients in Spanish primary care. This prevalence is higher in women, older individuals, and those with lower body mass index, highlighting a significant public health concern.

Area of Science:

  • Nephrology
  • Cardiology
  • Primary Care Medicine

Context:

  • Chronic kidney disease (CKD) is a growing public health concern with limited data on its prevalence in primary care settings.
  • Dyslipidemia is a common condition managed in primary care, often coexisting with other chronic diseases.
  • Assessing CKD in dyslipidemic patients is crucial for cardiovascular risk stratification and management.

Purpose:

  • To determine the prevalence of undetected CKD in a dyslipidemic population managed in primary care.
  • To utilize the Cockcroft-Gault equation corrected for surface area for estimating creatinine clearance and diagnosing CKD.
  • To identify sociodemographic and clinical factors associated with CKD in this patient group.

Summary:

  • A cross-sectional study of 5,990 dyslipidemic patients in primary care found a CKD prevalence of 16.2% using the Cockcroft-Gault equation.
  • CKD was significantly more prevalent in women (22.7%) than men (9.8%).
  • Factors associated with higher CKD probability included female gender, older age, and lower body mass index.

Impact:

  • The findings suggest that a substantial proportion of dyslipidemic patients in primary care have undiagnosed CKD, necessitating targeted screening.
  • Early detection of CKD in this population can lead to timely interventions, potentially reducing cardiovascular complications and disease progression.
  • This study underscores the importance of routine renal function assessment in patients with dyslipidemia within primary care settings.
Abstract

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...